Huons  said Tuesday it would build a second plant to manufacture eye drops at the BioValley in Jecheon, North Chungcheong Province.

The company will invest 40 billion won ($36 million) to construct the production and logistics center by 2022. It will produce seven types of eye drops by installing three state-of-the-art lines and transferring four others from its existing plant.  

According to Huons, the new factory’s annual production capacity is 480 million, up 60 percent from the current 300 million tubes to become the largest production capacity of eye drops in Korea.

The expansion will enable the company to introduce systemized inventory management and store 6,024 cells of medical products, more than double the 2,904 cells at the first plant. Simultaneously, the first plant will focus on producing cartridge injections, for which the company has received the certification for good manufacturing practice (cGMP). 

“We will expand cartridge injection productions by the third quarter of 2021 and respond to rising demand for exporting anesthetics to China, Japan, and the Middle East,” a Huons official said. “Plant 2 will also be built in line with cGMP standards to win approvals from the U.S. and EU.”

Huons Global CEO Um Ki-ahn also said, “For Huon’s growth, expanding the capacity is essential. We hope consumers will keep an eye on Huon’s stroll toward the global healthcare market.”